VEGFD and neoplasm: We have demonstrated for the first time that YL529 suppresses tumor lymphangiogenesis and lymphatic metastasis by down-regulation of VEGF-D in VEGF-D-LL/2 cancer cells and inhibiting neogenesis and tube formation of lymphatic endothelial cells directly through the VEGFR-3 pathway.